TICAM2 (TIR domain containing adaptor molecule 2), also known as TRAM, is a critical adaptor protein in toll-like receptor 4 (TLR4) signaling that mediates innate immune responses to bacterial lipopolysaccharide (LPS). 1 TICAM2 functions as a molecular scaffold that recruits signaling kinases and effectors to endosomal complexes, enabling the TRIF-dependent TLR4 signaling cascade following LPS-induced receptor endocytosis. 2 Mechanistically, TICAM2 activates downstream signaling through Src family kinases (SFK) and STAT1 phosphorylation, driving pro-inflammatory cytokine production and type I interferon responses. 3 In disease contexts, TICAM2 plays dual and complex roles. TICAM2 polymorphisms associate significantly with tuberculosis susceptibility (P = 3.6 × 10⁻⁶), suggesting genetic variation impacts mycobacterial immunity. 4,5 However, TICAM2 ablation protects mice from severe sepsis-induced inflammation and multi-organ injury by preventing prolonged neutrophil and monocyte exhaustion. 3,6 TICAM2-deficient monocytes recover from exhaustion faster after sepsis and exhibit altered epigenetic programming at immune regulatory genes. 6 Additionally, TICAM2 participates in parasite-host interactions, where it functions within a STING-IRF3-IDO1 signalosome that can paradoxically promote Toxoplasma gondii replication through tryptophan metabolism alterations. 7